Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 15 clinical trials
A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for Delta-Like Ligand 3 (DLL3).

To determine the maximum tolerated dose(s) (MTD) or the Recommended Dose for Expansion (RDE) and dosing regimen for further development of BI 764532. The MTDs will be defined based on the frequency of patients experiencing dose limiting toxicities (DLTs) during the MTD evaluation period in studied regimens. The Recommended Dose …

  • 0 views
  • 19 Feb, 2024
Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (NEOASIS)

In this study, the efficacy of botensilimab and balstilimab in mismatch repair deficient (dMMR) and mismatch repair proficient (pMMR) tumors will be assessed.

  • 0 views
  • 27 Feb, 2025
  • 1 location
Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (NEOASIS)

In this study, the efficacy of botensilimab and balstilimab in mismatch repair deficient (dMMR) and mismatch repair proficient (pMMR) tumors will be assessed.

  • 0 views
  • 02 Dec, 2024
  • 1 location
Hypofractionation And Ultra-Hypofractionation In Adjuvant Radiotherapy For Breast Cancer

Prospective randomized study comparing 5 fractions in alternative days to standard 15 fractions regarding effectiveness and feasibility during adjuvant treatment in breast caner patients aged above 50 years

breast cancer
cancer
adjuvant radiotherapy
x-rays
ct scan
  • 0 views
  • 19 Feb, 2024
Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276

Patients with refractory and/or recurrent solid tumor have poor prognosis despite complex multimodel therapy and therefore, novel approaches are urgently needed. This study attempts to treat these diseases using T cells genetically modified with a 4th generation lentiviral chimeric antigen receptor (4SCAR fused with an inducible apoptotic caspase 9 domain) …

tyrosine
antibody therapy
platelet count
serum bilirubin
growth factor
  • 0 views
  • 19 Feb, 2024
Exercise and Tumor Blood Flow in Breast Cancer Patients

This research aims at investigating tumor blood flow response to acute exercise in human cancer patients. It is hypothesized and expected that acute exercise increases tumor blood flow, which could plausibly increase the efficacy of cancer treatment.

cancer treatment
  • 0 views
  • 19 Feb, 2024
Evaluation of Clinical Radiomics and Molecular Features of Lung Metastasis in PDAC Patients (LUMACA Trial)

The aim of this study is the characterization from epidemiological, radiomics and molecular point of view of lung metastasis of patients at beginning affected by pancreatic adenocarcinoma (PDAC), which after the resection of primitive tumor have met with initial recurrence of the disease exclusively at the lung level.

pancreatic adenocarcinoma
metastasis
primary tumor
pdac
adenocarcinoma
  • 0 views
  • 19 Feb, 2024
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

Participants are assigned to one of 8 cohorts based on their primary tumour type: breast, lung, gastrointestinal (GI), primary unknown, genitourinary (GU), sarcoma, gynecological, and 'other' cancer types. Participants in all cohorts will receive the same dose of atezolizumab (1200 mg every 3 weeks). In the first stage for each …

absolute neutrophil count
gastrointestinal cancer
granulocyte colony stimulating factor
solid tumour
platelet count
  • 0 views
  • 19 Feb, 2024
Neoadjuvant T-VEC in High Risk Early Melanoma

Moreover, the application of these therapeutics has been limited in the neoadjuvant setting, particularly in earlier stage disease, even though this strategy has improved tolerance and efficacy with other modalities of therapy in other cancer types. Survival remains significantly poorer for thicker and ulcerated lesions with T3b and T4 lesions …

immunotherapies
cancer
platelet count
primary tumor
hysterectomy
  • 0 views
  • 19 Feb, 2024
Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.

measurable disease
multiple myeloma
  • 0 views
  • 19 Feb, 2024